|
Originally published In Press as doi:10.1074/jbc.M710251200 on January 16, 2008
J. Biol. Chem., Vol. 283, Issue 12, 7354-7360, March 21, 2008
Peters Plus Syndrome Is a New Congenital Disorder of Glycosylation and Involves Defective O-Glycosylation of Thrombospondin Type 1 Repeats*
Daniel Hess ,
Jeremy J. Keusch ,
Saskia A. Lesnik Oberstein ,
Raoul C. M. Hennekam¶||, and
Jan Hofsteenge 1
From the
Friedrich Miescher Institute for Biomedical Research, Basel CH-4058, Switzerland, the Center for Human and Clinical Genetics, Department of Clinical Genetics, K5-R, Leiden University Medical Center, 2300 RC Leiden, The Netherlands, the ¶Clinical and Molecular Genetics Unit, Institute of Child Health, London WC1N 3JH, United Kingdom, and the ||Department of Pediatrics, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
Peters Plus syndrome is an autosomal recessive disorder characterized by anterior eye chamber defects, disproportionate short stature, developmental delay, and cleft lip and/or palate. It is caused by splice site mutations in what was thought to be a β1,3-galactosyltransferase-like gene (B3GALTL). Recently, we and others found this gene to encode a β1,3-glucosyltransferase involved in the synthesis of the disaccharide Glc-β1,3-Fuc-O-that occurs on thrombospondin type 1 repeats of many biologically important proteins. No functional tests have been performed to date on the presumed glycosylation defect in Peters Plus syndrome. We have established a sensitive immunopurification-mass spectrometry method, using multiple reaction monitoring, to analyze O-fucosyl glycans. It was used to compare the reporter protein properdin from Peters Plus patients with that from control heterozygous relatives. In properdin from patients, we could not detect the Glc-β1,3-Fuc-O-disaccharide, and we only found Fuc-O-at all four O-fucosylation sites. In contrast, properdin from heterozygous relatives and a healthy volunteer carried the Glc-β1,3-Fuc-O-disaccharide. These data firmly establish Peters Plus syndrome as a new congenital disorder of glycosylation.
Received for publication, December 17, 2007
, and in revised form, January 16, 2008.
* This work was supported by the Novartis Research Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1–S4.
1 To whom correspondence should be addressed: Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, Basel CH-4058, Switzerland. Tel.: 41-61-6974722; Fax: 41-61-6973976; E-mail: jan.hofsteenge{at}fmi.ch.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|